We used a bacterially expressed fusion protein containing the entire cytoplasmic domain of the human leukemia inhibitory factor (LIF) receptor to study its phosphorylation in response to LIF stimulation. The dose-and time-dependent relationships for phosphorylation of this construct in extracts of LIF-stimulated 3T3-L1 cells were superimposable with those for the stimulation of mitogen-activated protein kinase (MAPK). Indeed, phosphorylation of the cytoplasmic domain of the low-affinity LIF receptor a-subunit (LIFR) in Mono Q-fractionated, LIF-stimulated 3T3-L1 extracts occurred only in those fractions containing activated MAPK; Ser-1044 served as the major phosphorylation site in the human LIFR for MAPK both in agonist-stimulated 3T3-L1 lysates and by recombinant extracellular signal-regulated kinase 2 in vitro. Expression in rat H-35 hepatoma cells of LIFR or chimeric granulocyte-colony-stimulating factor receptor (G-CSFR)-LIFR mutants lacking Ser-1044 failed to affect cytokinestimulated expression of a reporter gene under the control of the ,8-fibrinogen gene promoter but eliminated the insulin-induced attenuation of cytokine-stimulated gene expression. Thus, our results identify the human LIFR as a substrate for MAPK and suggest a mechanism ofheterologous receptor regulation ofLIFR signaling occurring at Ser-1044.
in vitro. Expression in rat H-35 hepatoma cells of LIFR or chimeric granulocyte-colony-stimulating factor receptor (G-CSFR)-LIFR mutants lacking
Ser-1044 failed to affect cytokinestimulated expression of a reporter gene under the control of the ,8-fibrinogen gene promoter but eliminated the insulin-induced attenuation of cytokine-stimulated gene expression. Thus, our results identify the human LIFR as a substrate for MAPK and suggest a mechanism ofheterologous receptor regulation ofLIFR signaling occurring at Ser-1044.
Leukemia inhibitory factor (LIF) is a member of the family of multifunctional cytokines capable of stimulating numerous physiological processes in a variety of cells (1, 2) . LIF, along with ciliary neurotrophic factor, interleukins (ILs) 6 and 11, and oncostatin M, constitutes a distinct subgroup of the cytokine family (3) in which each member has its own unique a-receptor subunit that associates with the shared receptor subunit gp130 to initiate transmembrane signaling (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Early studies of LIF signaling have indicated activation of a pathway(s) involving both Tyr and Ser/Thr protein kinases (12, 13) . Both the low-affinity LIF receptor a subunit (LIFR) and gpl3O associate with and stimulate members of the Jak/Tyk family of nonreceptor protein-tyrosine kinases (14) . We (15) and others (16, 17) have shown recently that activation of LIFR by agonist rapidly stimulates several components of the mitogen-activated protein kinase (MAPK) cascade, including MAPK kinase, the MAPK isozymes extracellular signal-regulated kinases (ERKs) 1 and 2, and S6 protein kinase activities against both S6 peptide and 40S ribosomes. In the current study, we show that the human LIFR can be phosphorylated at Ser-1044 by activated MAPK in vitro and suggest that this residue mediates a pathway for regulation of LIFR signaling after stimulation of a heterologous receptor system.
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MATERIALS AND METHODS Materials. Recombinant human LIF was purchased from Preprotech (Rocky Hill, NJ) or, together with granulocytecolony-stimulating factor (G-CSF), was (15) . The procedures for developing the column were as described (15) (10 gg/ml) receptor expression vectors (2.5 Ag/ml), and pIE-MUP (an internal marker for transfection efficiency; 2 gg/ml) as described (20) . The expression vectors (pDC302) containing the full-length wild-type human LIFR, the chimeric G-CSF receptor (G-CSFR)-LIFR(238), and the C-terminally truncated G-CSFR-LIFR(180) chimera (corresponding to position 1039 in the full-length LIFR) have been described (20) . These same expression vectors were used to generate Ala-1044-substituted mutants either in the full-length LIFR or in the chimeric G-CSFR-LIFR, yielding plasmids pLIFR(S1044A) and pG-CSFR-LIFR(S1044A), respectively. IL-6, LIF, and G-CSF were used when indicated at 100 ng/ml. In some experiments, the effects of heterologous receptor activation on LIFRstimulated gene induction were tested by treating identically prepared H-35 transfectants with 0.5 ,uM insulin either concomitantly with or 24 hr prior to addition of cytokine. Data are presented as the mean fold simulations ± SD relative to control values, and statistical significance (P < 0.05) was analyzed by unpaired Student's t test.
RESULTS
Signal transduction mediated by activated LIFRs requires the dual stimulation of both Tyr and Ser/Thr protein kinases (12) (13) (14) (15) (16) (17) ; gpl3O, in response to agonist stimulation, contains elevated levels of phosphotyrosine, phosphoserine, and phosphothreonine (21) . To determine if cLIFR could be similarly phosphorylated after LIF stimulation, we incubated extracts of 3T3-L1 cells with several GST fusion proteins containing all or various regions of cLIFR and measured their ability to serve as substrates in protein kinase reactions. Treatment of quiescent 3T3-L1 cells with LIF rapidly stimulated phosphorylation of the full-length LIFR fusion protein construct, GST-cLIFR/ 856-1097, which peaked at 10 min and then declined to basal levels by 60 min (Fig. 1) . Phosphotransferase activity against this construct, which occurred predominantly on Ser residues (data not shown), was stimulated in a dose-dependent manner and exhibited half-maximal stimulation (EC5o) at '15 ng/ml (0.75 nM; data not shown). Interestingly, the time course ( Fig.  1 ) and dose-response (data not shown) curves for LIFstimulated phosphorylation of GST-cLIFR/856-1097 were indistinguishable from those for MBP. Because we have shown previously that phosphorylation of MBP in LIF-stimulated lysates correlates with activation of the MAPK isozymes ERK1 and ERK2 (15), these results suggested that some of the phosphorylation of the LIFR construct in 3T3-L1 extracts may be mediated by activated MAPK.
Stimulation of 3T3-L1 cells with insulin, EGF, or phorbol 12-myristate 13-acetate, which activate MAPK in these cells (15) , also resulted in the activation of phosphotransferase activity against GST-cLIFR/856-1097 (Fig. 2, lanes 1) . Truncation of the 60 C-terminal amino acids blocked agoniststimulated phosphorylation of the LIFR ( Fig. 2; GST-cLIFR/ 856-1037; lanes 2), while constructs containing all ( Fig. 2 ; GST-cLIFR/1005-1097; lanes 3) or part ( Fig. 2 (Fig. 3) . In accord with our previous results (15), immunoreactivity against anti-MAPK-7884 antibody confirmed the presence of the MAPK isozymes ERK2 and ERK1 in peaks one and two, respectively (data not shown). Interestingly, phosphorylation of GST-cLIFR/856-1097 is detectable only in those fractions containing LIF-stimulated ERK2 and ERK1 (Fig. 3) . Thus, activated MAPK represents a major protein kinase activity against the human LIFR in LIF-stimulated lysates.
We also found that in vitro-activated recombinant ERK2
readily phosphorylates GST-cLIFR/856-1097, with the enzyme incorporating 0.90 ± 0.36 (mean + SD; n = 2) mol of phosphate per mol of fusion protein with an apparent affinity (Km) of 3.86 ± 1.72 .tkM (0.21 mg/ml; mean ± SD; n = 3).
Phosphorylation of GST-cLIFR/856-1097 occurred almost exclusively on Ser residues, and, as in agonist-stimulated lysates, truncation of the 60 C-terminal amino acids blocked the ability of recombinant ERK2 to phosphorylate the LIFR (Fig. 4) . The MAPK phosphorylation consensus site is Pro-Xaa-Ser/ Thr-Pro (22) , but the Pro at position -2 is not absolutely required for MAPK-mediated phosphorylation. By these criteria, there are four potential MAPK phosphorylation sites contained within the 60 C-terminal amino acids of the human LIFR, located at Ser-1041, Ser-1044, Ser-1059, and Ser-1077. We mutated, both in singular and in multiple combinations, these Ser residues to Ala and then tested their ability to be phosphorylated both by LIF-stimulated lysates and by recombinant ERK2. Only Ala substitution at Ser-1044 significantly diminished LIFR phosphorylation by MAPK, blocking =80% and =70% of wild-type (GST-cLIFR/1097) phosphorylation in LIF-stimulated extracts and by recombinant ERK2, respectively (Fig. 5) . Furthermore, GST-cLIFR(Ala-1044) exhibited ;>% E Extracts of LIF-stimulated 3T3-L1 cells (100 ng/ml for 10 min at 37°C) were fractionated over the anion-exchanger Mono Q. The dashed lines (----) approximate the linear NaCl gradient (0-350 mM) used to elute bound proteins collected every 2 min in 1-ml volumes. Determination of phosphotransferase activity against MBP (0), GST-cLIFR/856-1097 (0), and GST-cLIFR(Ala-1044) (m) was carried out as described in Materials and Methods. Protein kinase activities are plotted as the percentage of maximal peak height for each substrate, except for GST-cLIFR(Ala-1044), which was normalized to GST-cLIFR/856-1097. Data are representative of a single column run, which was repeated three times with similar results, except for activities against GST-cLIFR(Ala-1044), which was performed once. <30% of total ERK phosphorylation (=30% of ERK2 and -23% of ERK1 phosphorylation, respectively) of the LIFR when compared to wild-type levels in Mono Q-fractionated 3T3-L1 extracts (Fig. 3) . Thus, the major phosphorylation site in the LIFR for active MAPK, both in LIF-stimulated extracts and by recombinant ERK2, is Ser-1044.
We 11-fold) . Similarly, expression of either chimeric G-CSF-LIFR(238) or G-CSF-LIFR(S1044A) was equally effective in inducing CAT expression in H-35 cells stimulated with G-CSF ( Table 1) . These results suggest that cytokine stimulation, which should lead to phosphorylation of the LIFR at Ser-1044, is insufficient in altering, either positively or negatively, LIFR-mediated gene induction occurring at IL-6-responsive elements. In addition, extended culture times did not alter the extent of G-CSFmediated CAT expression in H-35 cells expressing either wild-type or Ala-1044-substituted G-CSFR-LIFR chimeras ( Table 1 ), suggesting that phosphorylation at Ser-1044 does not dramatically alter LIFR turnover.
Last, we investigated whether activation of a heterologous receptor system could modulate LIFR signaling through effects at Ser-1044. Coadministration of insulin (0.5,uM) to H-35 transfectants significantly reduced the extent of LIFstimulated CAT expression (Table 1) . Furthermore, this insulin-induced attenuation of LIFR signaling was even greater in cells expressing chimeric G-CSFR-LIFR(238) receptors (Table 1 ). The inhibitory effects of insulin on G-CSF- consisting of p,BFB(350)-CAT (10 ,ug/ml), pIE-MUP (2 ,ug/ml), and receptor expression vectors (2.5 j,g/ml) as indicated. After a 16-hr recovery period, the transfected cell cultures were subdivided into appropriate dishes and were subsequently stimulated and assayed for specific CAT tSignificant reduction from matched G-CSF treatment (P < 0.05) and significant reduction from mutant chimeric G-CSFR-LIFR values determined in the presence of insulin (P < 0.05).
stimulated CAT expression were completely lost in G-CSFR-LIFR(S1044A)-expressing cells ( Table 1 ), suggesting that insulin-mediated inhibition of LIFR-stimulated CAT induction occurs at Ser-1044. Consistent with this hypothesis is our finding that activation of G-CSFR-LIFR(180), which lacks amino acids 1040-1097 of the LIFR, was also insensitive to the inhibitory effects of insulin ( The finding that Ala-1040-substituted chimeric G-CSFR-LIFR mutants or C-terminally truncated chimeric G-CSFR-LIFR constructs lacking Ser-1044 were completely resistant to the inhibitory effects of insulin on cytokine-stimulated CAT expression in H-35 cells indicates that, in addition to its effects at the level of transcription (23), the major site of action for insulin-mediated inhibition of LIF-stimulated CAT induction occurs at the level of the LIFR itself.
Because both insulin (24) and LIF (15) (16) (17) (20) , designated boxes 1, 2, and 3, which function in a cooperative manner to regulate LIF-mediated gene induction in both hepatic and neuronal cell lines (20) . These regions in heterodimeric LIFR-gp13O complexes stimulate at lest two types of gene-inductive signals, one targeting cytokine responsive elements generated from boxes 1 and 2, and a second targeting IL-6-responsive elements involving the actions of boxes 1,2, and 3 (25) . Ser-1044 lies "40 amino acids C-terminal to the end of box 3. The ability of insulin to inhibit LIF-stimulated p,BFB(350)-CAT expression, which requires the cooperative interaction of boxes 1, 2, and 3 for maximal induction, raises the possibility that phosphorylation of the human LIFR by MAPK may uncouple LIFmediated gene induction from IL-6 response elements but not necessarily those from cytokine response elements. Alternatively, phosphorylation at Ser-1044 of the human LIFR may alter the substrate specificity of its associated nonreceptor protein-tyrosine kinases or modulate, either positively or negatively, the coupling of activated LIFRs to various activators of the MAPK cascade.
Finally, while Ala-1044-containing chimeric G-CSFR-LIFR constructs are insensitive to the inhibitory effects of insulin, the responsiveness to insulin of wild-type or LIFR(S1044A) receptors on Hep3B cells was less dramatic than those determined for their chimeric counterparts on H-35 cells (data not shown). Although the varying sensitivity of these receptors to insulin could reflect specific cell or reporter gene (rat haptoglobin promoter) differences, this effect might also be explained by the presence and functioning of gp13O within the heterodimeric receptor complexes. Indeed, we have recently found that gpl3O is phosphorylated on Ser residues C-terminal to box 3 in response to LIF stimulation by a protein kinase distinct from MAPK (W.P.S. and N.M.N., unpublished observation). Thus, phosphorylation and regulation of human LIFRs may require the actions of two distinct protein kinases, each targeting specific phosphorylation sites in the LIFR (MAPK at Ser-1044) and in gpl3O (unknown protein kinase).
In summary, we have shown that Ser-1044 of the human LIFR is a substrate for activated MAPK. Moreover, Ser-1044 is required for heterologous receptor regulation of LIFR signaling in H-35 cells. Although additional studies will be required to fully elucidate the role of Ser-1044 in LIFR signaling, its localization places this residue adjacent to conserved intracellular cytokine receptor sequence motifs known to function in regulating growth and differentiation signals.
